A detailed guide for the use of GlaxoSmithKline's sotrovimab under Emergency Use Authorization (EUA) for treating mild-to-moderate COVID-19 in adults and…
This document serves as a comprehensive resource for healthcare providers regarding the administration of sotrovimab, an unapproved monoclonal antibody authorized by the FDA under an Emergency Use Authorization (EUA). It outlines specific patient populations eligible for treatment, mandatory requirements for administration, and important safety information. The guide emphasizes that sotrovimab is not authorized for hospitalized patients or those requiring oxygen therapy due to COVID-19.
Sotrovimab is authorized for adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive SARS-CoV-2 viral testing who are at high risk for progression to severe COVID-19.
Sotrovimab should be administered by intravenous infusion as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset.
No, sotrovimab is not authorized for use in patients who are hospitalized due to COVID-19 or those requiring oxygen therapy.